ReviewFrontiers in oncology2020

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Kartik Sehgal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.